Antibiotic Use Does Not Appear to Influence Response to Nivolumab
Microbiota is known to influence response to anticancer immunotherapy. We examined whether antibiotic usage could impact nivolumab efficacy in patients treated for non-small-cell lung cancer (NSCLC). Seventy-four patients with NSCLC were included in this retrospective study. They received nivolumab...
Gespeichert in:
| Veröffentlicht in: | Anticancer research 2017-06, Vol.37 (6), p.3195-3200 |
|---|---|
| Hauptverfasser: | , , , , , , , , , , |
| Format: | Artikel |
| Sprache: | eng |
| Schlagworte: | |
| Online-Zugang: | Volltext |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| container_end_page | 3200 |
|---|---|
| container_issue | 6 |
| container_start_page | 3195 |
| container_title | Anticancer research |
| container_volume | 37 |
| creator | Kaderbhai, Coureche Richard, Corentin Fumet, Jean David Aarnink, Anne Foucher, Pascal Coudert, Bruno Favier, Laure Lagrange, Aurélie Limagne, Emeric Boidot, Romain Ghiringhelli, Francois |
| description | Microbiota is known to influence response to anticancer immunotherapy. We examined whether antibiotic usage could impact nivolumab efficacy in patients treated for non-small-cell lung cancer (NSCLC).
Seventy-four patients with NSCLC were included in this retrospective study. They received nivolumab between 2015 and 2016 (3 mg/kg i.v. q2w). The association between RECIST response and antibiotic usage was determined using Chi-square and Cox proportional hazard model.
A total of 17, 21 and 36 patients experienced response, stable disease and progression disease under nivolumab. Only 15 (20.3%) patients were exposed to antibiotic medication in the 3 months before the first nivolumab injection or during treatment. We found a similar response rate for the two populations, without impact of antibiotic exposure (Chi-square test p=0.75). Moreover, we observed no impact of antibiotic medication on progression-free survival under nivolumab (log-rank test, p=0.72).
Microbiota modification induced by antibiotics does not appear to affect the efficacy of nivolumab in patients with NSCLC. |
| doi_str_mv | 10.21873/anticanres.11680 |
| format | Article |
| fullrecord | <record><control><sourceid>proquest_hal_p</sourceid><recordid>TN_cdi_hal_primary_oai_HAL_hal_01545832v1</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>1903438329</sourcerecordid><originalsourceid>FETCH-LOGICAL-c378t-db28d8e2f1e658ab807e1785d23d74361e6819d41e4a643e08071904b3375d873</originalsourceid><addsrcrecordid>eNpFkF1LwzAUhoMobk5_gDfSS73ozGmSJr0s82PCmCDuOqTtKVbapjbtwH9v3Oa8OvDyvA-cl5BroPMIlGT3ph2q3LQ9ujlArOgJmYJMIJSC0VMypZGgoaRUTMiFc5-UxnGi2DmZREoIiGM-JWnqFVllvSfYOAweLLpgbYcg7To0fTDY4KUt6xHbHIM3dJ1tPeXTdbW19diY7JKclaZ2eHW4M7J5enxfLMPV6_PLIl2FOZNqCIssUoXCqASMhTKZohJBKlFErJCcxT5WkBQckJuYM6QegITyjDEpCv_sjNztvR-m1l1fNab_1tZUepmu9G9GQXChWLQFz97u2a63XyO6QTeVy7GuTYt2dNqLGWeeTTwKezTvrXM9lkc3UL1bWf-vrHcr-87NQT9mDRbHxt-s7AfcjXgY</addsrcrecordid><sourcetype>Open Access Repository</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>1903438329</pqid></control><display><type>article</type><title>Antibiotic Use Does Not Appear to Influence Response to Nivolumab</title><source>MEDLINE</source><source>EZB-FREE-00999 freely available EZB journals</source><creator>Kaderbhai, Coureche ; Richard, Corentin ; Fumet, Jean David ; Aarnink, Anne ; Foucher, Pascal ; Coudert, Bruno ; Favier, Laure ; Lagrange, Aurélie ; Limagne, Emeric ; Boidot, Romain ; Ghiringhelli, Francois</creator><creatorcontrib>Kaderbhai, Coureche ; Richard, Corentin ; Fumet, Jean David ; Aarnink, Anne ; Foucher, Pascal ; Coudert, Bruno ; Favier, Laure ; Lagrange, Aurélie ; Limagne, Emeric ; Boidot, Romain ; Ghiringhelli, Francois</creatorcontrib><description>Microbiota is known to influence response to anticancer immunotherapy. We examined whether antibiotic usage could impact nivolumab efficacy in patients treated for non-small-cell lung cancer (NSCLC).
Seventy-four patients with NSCLC were included in this retrospective study. They received nivolumab between 2015 and 2016 (3 mg/kg i.v. q2w). The association between RECIST response and antibiotic usage was determined using Chi-square and Cox proportional hazard model.
A total of 17, 21 and 36 patients experienced response, stable disease and progression disease under nivolumab. Only 15 (20.3%) patients were exposed to antibiotic medication in the 3 months before the first nivolumab injection or during treatment. We found a similar response rate for the two populations, without impact of antibiotic exposure (Chi-square test p=0.75). Moreover, we observed no impact of antibiotic medication on progression-free survival under nivolumab (log-rank test, p=0.72).
Microbiota modification induced by antibiotics does not appear to affect the efficacy of nivolumab in patients with NSCLC.</description><identifier>ISSN: 0250-7005</identifier><identifier>EISSN: 1791-7530</identifier><identifier>DOI: 10.21873/anticanres.11680</identifier><identifier>PMID: 28551664</identifier><language>eng</language><publisher>Greece: International Institute of Anticancer Research</publisher><subject>Aged ; Aged, 80 and over ; Anti-Bacterial Agents - adverse effects ; Anti-Bacterial Agents - therapeutic use ; Antibodies, Monoclonal - adverse effects ; Antibodies, Monoclonal - therapeutic use ; Antineoplastic Agents - adverse effects ; Antineoplastic Agents - therapeutic use ; Cancer ; Carcinoma, Non-Small-Cell Lung - drug therapy ; Carcinoma, Non-Small-Cell Lung - mortality ; Carcinoma, Non-Small-Cell Lung - pathology ; Chi-Square Distribution ; Disease-Free Survival ; Female ; France ; Humans ; Kaplan-Meier Estimate ; Life Sciences ; Lung Neoplasms - drug therapy ; Lung Neoplasms - mortality ; Lung Neoplasms - pathology ; Male ; Middle Aged ; Polypharmacy ; Proportional Hazards Models ; Retrospective Studies ; Risk Factors ; Time Factors ; Treatment Outcome</subject><ispartof>Anticancer research, 2017-06, Vol.37 (6), p.3195-3200</ispartof><rights>Copyright© 2017, International Institute of Anticancer Research (Dr. George J. Delinasios), All rights reserved.</rights><rights>Distributed under a Creative Commons Attribution 4.0 International License</rights><lds50>peer_reviewed</lds50><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c378t-db28d8e2f1e658ab807e1785d23d74361e6819d41e4a643e08071904b3375d873</citedby><orcidid>0000-0001-9732-0219</orcidid></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><link.rule.ids>230,314,780,784,885,27924,27925</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/28551664$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink><backlink>$$Uhttps://hal.science/hal-01545832$$DView record in HAL$$Hfree_for_read</backlink></links><search><creatorcontrib>Kaderbhai, Coureche</creatorcontrib><creatorcontrib>Richard, Corentin</creatorcontrib><creatorcontrib>Fumet, Jean David</creatorcontrib><creatorcontrib>Aarnink, Anne</creatorcontrib><creatorcontrib>Foucher, Pascal</creatorcontrib><creatorcontrib>Coudert, Bruno</creatorcontrib><creatorcontrib>Favier, Laure</creatorcontrib><creatorcontrib>Lagrange, Aurélie</creatorcontrib><creatorcontrib>Limagne, Emeric</creatorcontrib><creatorcontrib>Boidot, Romain</creatorcontrib><creatorcontrib>Ghiringhelli, Francois</creatorcontrib><title>Antibiotic Use Does Not Appear to Influence Response to Nivolumab</title><title>Anticancer research</title><addtitle>Anticancer Res</addtitle><description>Microbiota is known to influence response to anticancer immunotherapy. We examined whether antibiotic usage could impact nivolumab efficacy in patients treated for non-small-cell lung cancer (NSCLC).
Seventy-four patients with NSCLC were included in this retrospective study. They received nivolumab between 2015 and 2016 (3 mg/kg i.v. q2w). The association between RECIST response and antibiotic usage was determined using Chi-square and Cox proportional hazard model.
A total of 17, 21 and 36 patients experienced response, stable disease and progression disease under nivolumab. Only 15 (20.3%) patients were exposed to antibiotic medication in the 3 months before the first nivolumab injection or during treatment. We found a similar response rate for the two populations, without impact of antibiotic exposure (Chi-square test p=0.75). Moreover, we observed no impact of antibiotic medication on progression-free survival under nivolumab (log-rank test, p=0.72).
Microbiota modification induced by antibiotics does not appear to affect the efficacy of nivolumab in patients with NSCLC.</description><subject>Aged</subject><subject>Aged, 80 and over</subject><subject>Anti-Bacterial Agents - adverse effects</subject><subject>Anti-Bacterial Agents - therapeutic use</subject><subject>Antibodies, Monoclonal - adverse effects</subject><subject>Antibodies, Monoclonal - therapeutic use</subject><subject>Antineoplastic Agents - adverse effects</subject><subject>Antineoplastic Agents - therapeutic use</subject><subject>Cancer</subject><subject>Carcinoma, Non-Small-Cell Lung - drug therapy</subject><subject>Carcinoma, Non-Small-Cell Lung - mortality</subject><subject>Carcinoma, Non-Small-Cell Lung - pathology</subject><subject>Chi-Square Distribution</subject><subject>Disease-Free Survival</subject><subject>Female</subject><subject>France</subject><subject>Humans</subject><subject>Kaplan-Meier Estimate</subject><subject>Life Sciences</subject><subject>Lung Neoplasms - drug therapy</subject><subject>Lung Neoplasms - mortality</subject><subject>Lung Neoplasms - pathology</subject><subject>Male</subject><subject>Middle Aged</subject><subject>Polypharmacy</subject><subject>Proportional Hazards Models</subject><subject>Retrospective Studies</subject><subject>Risk Factors</subject><subject>Time Factors</subject><subject>Treatment Outcome</subject><issn>0250-7005</issn><issn>1791-7530</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2017</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><recordid>eNpFkF1LwzAUhoMobk5_gDfSS73ozGmSJr0s82PCmCDuOqTtKVbapjbtwH9v3Oa8OvDyvA-cl5BroPMIlGT3ph2q3LQ9ujlArOgJmYJMIJSC0VMypZGgoaRUTMiFc5-UxnGi2DmZREoIiGM-JWnqFVllvSfYOAweLLpgbYcg7To0fTDY4KUt6xHbHIM3dJ1tPeXTdbW19diY7JKclaZ2eHW4M7J5enxfLMPV6_PLIl2FOZNqCIssUoXCqASMhTKZohJBKlFErJCcxT5WkBQckJuYM6QegITyjDEpCv_sjNztvR-m1l1fNab_1tZUepmu9G9GQXChWLQFz97u2a63XyO6QTeVy7GuTYt2dNqLGWeeTTwKezTvrXM9lkc3UL1bWf-vrHcr-87NQT9mDRbHxt-s7AfcjXgY</recordid><startdate>20170601</startdate><enddate>20170601</enddate><creator>Kaderbhai, Coureche</creator><creator>Richard, Corentin</creator><creator>Fumet, Jean David</creator><creator>Aarnink, Anne</creator><creator>Foucher, Pascal</creator><creator>Coudert, Bruno</creator><creator>Favier, Laure</creator><creator>Lagrange, Aurélie</creator><creator>Limagne, Emeric</creator><creator>Boidot, Romain</creator><creator>Ghiringhelli, Francois</creator><general>International Institute of Anticancer Research</general><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>7X8</scope><scope>1XC</scope><orcidid>https://orcid.org/0000-0001-9732-0219</orcidid></search><sort><creationdate>20170601</creationdate><title>Antibiotic Use Does Not Appear to Influence Response to Nivolumab</title><author>Kaderbhai, Coureche ; Richard, Corentin ; Fumet, Jean David ; Aarnink, Anne ; Foucher, Pascal ; Coudert, Bruno ; Favier, Laure ; Lagrange, Aurélie ; Limagne, Emeric ; Boidot, Romain ; Ghiringhelli, Francois</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c378t-db28d8e2f1e658ab807e1785d23d74361e6819d41e4a643e08071904b3375d873</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2017</creationdate><topic>Aged</topic><topic>Aged, 80 and over</topic><topic>Anti-Bacterial Agents - adverse effects</topic><topic>Anti-Bacterial Agents - therapeutic use</topic><topic>Antibodies, Monoclonal - adverse effects</topic><topic>Antibodies, Monoclonal - therapeutic use</topic><topic>Antineoplastic Agents - adverse effects</topic><topic>Antineoplastic Agents - therapeutic use</topic><topic>Cancer</topic><topic>Carcinoma, Non-Small-Cell Lung - drug therapy</topic><topic>Carcinoma, Non-Small-Cell Lung - mortality</topic><topic>Carcinoma, Non-Small-Cell Lung - pathology</topic><topic>Chi-Square Distribution</topic><topic>Disease-Free Survival</topic><topic>Female</topic><topic>France</topic><topic>Humans</topic><topic>Kaplan-Meier Estimate</topic><topic>Life Sciences</topic><topic>Lung Neoplasms - drug therapy</topic><topic>Lung Neoplasms - mortality</topic><topic>Lung Neoplasms - pathology</topic><topic>Male</topic><topic>Middle Aged</topic><topic>Polypharmacy</topic><topic>Proportional Hazards Models</topic><topic>Retrospective Studies</topic><topic>Risk Factors</topic><topic>Time Factors</topic><topic>Treatment Outcome</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Kaderbhai, Coureche</creatorcontrib><creatorcontrib>Richard, Corentin</creatorcontrib><creatorcontrib>Fumet, Jean David</creatorcontrib><creatorcontrib>Aarnink, Anne</creatorcontrib><creatorcontrib>Foucher, Pascal</creatorcontrib><creatorcontrib>Coudert, Bruno</creatorcontrib><creatorcontrib>Favier, Laure</creatorcontrib><creatorcontrib>Lagrange, Aurélie</creatorcontrib><creatorcontrib>Limagne, Emeric</creatorcontrib><creatorcontrib>Boidot, Romain</creatorcontrib><creatorcontrib>Ghiringhelli, Francois</creatorcontrib><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>MEDLINE - Academic</collection><collection>Hyper Article en Ligne (HAL)</collection><jtitle>Anticancer research</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Kaderbhai, Coureche</au><au>Richard, Corentin</au><au>Fumet, Jean David</au><au>Aarnink, Anne</au><au>Foucher, Pascal</au><au>Coudert, Bruno</au><au>Favier, Laure</au><au>Lagrange, Aurélie</au><au>Limagne, Emeric</au><au>Boidot, Romain</au><au>Ghiringhelli, Francois</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Antibiotic Use Does Not Appear to Influence Response to Nivolumab</atitle><jtitle>Anticancer research</jtitle><addtitle>Anticancer Res</addtitle><date>2017-06-01</date><risdate>2017</risdate><volume>37</volume><issue>6</issue><spage>3195</spage><epage>3200</epage><pages>3195-3200</pages><issn>0250-7005</issn><eissn>1791-7530</eissn><abstract>Microbiota is known to influence response to anticancer immunotherapy. We examined whether antibiotic usage could impact nivolumab efficacy in patients treated for non-small-cell lung cancer (NSCLC).
Seventy-four patients with NSCLC were included in this retrospective study. They received nivolumab between 2015 and 2016 (3 mg/kg i.v. q2w). The association between RECIST response and antibiotic usage was determined using Chi-square and Cox proportional hazard model.
A total of 17, 21 and 36 patients experienced response, stable disease and progression disease under nivolumab. Only 15 (20.3%) patients were exposed to antibiotic medication in the 3 months before the first nivolumab injection or during treatment. We found a similar response rate for the two populations, without impact of antibiotic exposure (Chi-square test p=0.75). Moreover, we observed no impact of antibiotic medication on progression-free survival under nivolumab (log-rank test, p=0.72).
Microbiota modification induced by antibiotics does not appear to affect the efficacy of nivolumab in patients with NSCLC.</abstract><cop>Greece</cop><pub>International Institute of Anticancer Research</pub><pmid>28551664</pmid><doi>10.21873/anticanres.11680</doi><tpages>6</tpages><orcidid>https://orcid.org/0000-0001-9732-0219</orcidid><oa>free_for_read</oa></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 0250-7005 |
| ispartof | Anticancer research, 2017-06, Vol.37 (6), p.3195-3200 |
| issn | 0250-7005 1791-7530 |
| language | eng |
| recordid | cdi_hal_primary_oai_HAL_hal_01545832v1 |
| source | MEDLINE; EZB-FREE-00999 freely available EZB journals |
| subjects | Aged Aged, 80 and over Anti-Bacterial Agents - adverse effects Anti-Bacterial Agents - therapeutic use Antibodies, Monoclonal - adverse effects Antibodies, Monoclonal - therapeutic use Antineoplastic Agents - adverse effects Antineoplastic Agents - therapeutic use Cancer Carcinoma, Non-Small-Cell Lung - drug therapy Carcinoma, Non-Small-Cell Lung - mortality Carcinoma, Non-Small-Cell Lung - pathology Chi-Square Distribution Disease-Free Survival Female France Humans Kaplan-Meier Estimate Life Sciences Lung Neoplasms - drug therapy Lung Neoplasms - mortality Lung Neoplasms - pathology Male Middle Aged Polypharmacy Proportional Hazards Models Retrospective Studies Risk Factors Time Factors Treatment Outcome |
| title | Antibiotic Use Does Not Appear to Influence Response to Nivolumab |
| url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-01-05T10%3A12%3A29IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_hal_p&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Antibiotic%20Use%20Does%20Not%20Appear%20to%20Influence%20Response%20to%20Nivolumab&rft.jtitle=Anticancer%20research&rft.au=Kaderbhai,%20Coureche&rft.date=2017-06-01&rft.volume=37&rft.issue=6&rft.spage=3195&rft.epage=3200&rft.pages=3195-3200&rft.issn=0250-7005&rft.eissn=1791-7530&rft_id=info:doi/10.21873/anticanres.11680&rft_dat=%3Cproquest_hal_p%3E1903438329%3C/proquest_hal_p%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=1903438329&rft_id=info:pmid/28551664&rfr_iscdi=true |